Aignostics was founded in 2018 as a spin-off from Charite Berlin, one of the world's largest and most prestigious university hospitals, with a mission to bring the power of AI to pathology — the analysis of tissue at the cellular level that underpins cancer diagnosis and drug development. Pathology generates enormous volumes of richly detailed image data, but extracting reproducible, quantitative insight from it has historically required scarce expert time. Aignostics builds AI models, including pathology foundation models, that can read whole-slide images and surface biomarkers, patterns, and predictions at scale.
The company's primary commercial focus is biopharma. Drug developers need to identify which patients will respond to a therapy, discover novel biomarkers, and analyze tissue from clinical trials with consistency and speed. Aignostics' models support these workflows, helping pharmaceutical partners stratify patients, validate targets, and accelerate the research that brings precision-medicine therapies to market. Its differentiation lies in combining academic rigor — rooted in its Charite origins — with foundation-model approaches built specifically for the unique characteristics of histopathology data.
In October 2024 Aignostics raised an oversubscribed $34M (about €31.4M) Series B led by ATHOS, with strategic investment from Mayo Clinic and growth financing from HTGF, alongside existing investors Wellington Partners, Boehringer Ingelheim Venture Fund, CARMA Fund, and VC Fonds Technologie managed by IBB Ventures. The round brought total funding to over $55M. The Mayo Clinic relationship is especially significant: beyond capital, it positions Aignostics to develop leading pathology foundation models using one of the most respected clinical institutions in the world as a collaborator, and supports expansion into the U.S. market.
Aignostics' customers are pharmaceutical companies and research institutions pursuing precision medicine, particularly in oncology where tissue analysis is central. The company's strategic bet is that pathology, like radiology before it, is undergoing a digital and AI transformation, and that purpose-built foundation models trained on high-quality clinical data will become essential infrastructure for both drug development and, eventually, clinical diagnostics. With a strong scientific pedigree, a marquee clinical partner, and a clear biopharma go-to-market, Aignostics is positioned as a leading European player in computational pathology.